Pegfilgrastim: profile and news

Research and Markets: Aranesp, Neulasta and Enbrel have all Shown ... 16 May 2006
Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony ... - Genetic Engineering News,

Dose-Dense Therapy for NHL Safely Administered with Support of ... Apr 18, 2006
Among patients with diffuse large B-cell lymphoma, supportive treatment with Neulasta® (pegfilgrastim) allowed for the safe administration of the dose-dense ... - Cancer Consultants (press release),

Dose-Dense Adjuvant Chemotherapy for Node-Positive Breast Cancer ... May 5, 2006
...effect of suppressed blood cell production, researchers have administered a granulocyte colony-stimulating factor, such as Neupogen or Neulasta® (pegfilgrastim ... - Cancer Consultants (press release),

Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ... Apr 20, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 13 percent to $896 million in the first quarter of 2006 versus ... - Webbolt Business News,

Further Evidence that Chemotherapy-Induced Neutropenia Results in ... Apr 17, 2006
Agents such as Neulasta® (pegfilgrastim), which can prevent chemotherapy-induced neutropenia, may play an important role for patients with cancer. ... - Cancer Consultants (press release),

Other information

Indication
Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant

Pharmacology
Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.

Mechanism Of Action
Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase

Drug Category
Immunomodulatory Agents; Anti-infective Agents; Antineutropenic Agents; hematopoietic agents (20:16.00)

Brand Names/Synonyms
Granulocyte colony-stimulating factor precursor;G-CSF;Pluripoietin;Filgrastim;Lenograstim; Neulasta (Amgen Inc.)

Dosage Forms
SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
PEGylated human granulocyte colony stimulating factor

Chemical Formula
C845H1343N223O243S9

Half Life
15-80 hrs

Drug Type
Approved Drug

# Accession No
BIOD00094

CAS Registry Number
208265-92-3